THE SELECTION OF HARD CLINICAL ENDPOINTS VERSUS SURROGATE ENDPOINTS AS THE PRIMARY OUTCOME MEASURE IN MAJOR CARDIOVASCULAR CLINICAL TRIALS IS NOT INFLUENCED BY THE SOURCE OF FUNDING  by Aneja, Ashish et al.
A132.E1236
JACC March 9, 2010
Volume 55, issue 10A
 QUALITY OF CARE AND OUTCOMES ASSESSMENT 
THE SELECTION OF HARD CLINICAL ENDPOINTS VERSUS SURROGATE ENDPOINTS AS THE PRIMARY 
OUTCOME MEASURE IN MAJOR CARDIOVASCULAR CLINICAL TRIALS IS NOT INFLUENCED BY THE 
SOURCE OF FUNDING
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Outcomes Research: Appropriateness and Clinical Trials Reporting
Abstract Category: Appropriateness, Pay for Performance, Cost of Care
Presentation Number: 1031-180
Authors: Ashish Aneja, Ricardo Esquitin, Kshitij Shah, Louai Razzouk, Rupa Iyengar, Irfan Wali, Verghese Mathew, Michael E. Farkouh, MetroHealth 
Medical Center Campus of Case Western Reserve University, Cleveland, OH, Mount Sinai School of Medicine, New York, NY
Background: Some recent major cardiovascular (CV) trials have been faulted for utilizing surrogate instead of clinical endpoints. Selection of 
surrogate endpoints is thought to be driven by financial factors- smaller sample size, shorter follow up, and a potentially larger effect. It remains 
unknown whether sponsorship/funding source of major cardiovascular trials published in high impact journals influences the choice of clinical vis-a-
vis surrogate endpoints for primary outcomes. In addition, the frequency of safety endpoints has not been previously reported in CV trials.
Methods: We conducted a pubmed search for consecutive cardiovascular articles in the New England Journal of Medicine (NEJM), Journal of the 
American Medical Association (JAMA), and the Lancet between January 2000 and April 2008 as part of the Clinical Trials Reporting Database (CTRD). 
Articles were analyzed for their primary endpoints, which were sub-classified into clinical or surrogate. Articles with a primary outcome such as death 
and MI were classified as having a clinical endpoint, and a surrogate endpoint if the primary outcome was a lab value or imaging parameter.
Results: Of the 567 CV publications reviewed, 217 were in the NEJM, 184 in JAMA, and 166 in Lancet. Of the 540 with a funding source identified, 
273 were entirely industry funded, 53 NIH-sponsored, and 214 a combination of industry and not-for-profit organization; 336 were drug trials, 53 
evaluated devices or technological advancements, and 178 other interventions. In trials sponsored by industry, 220 of 269 (81.7%) reported a 
primary clinical endpoint vs. 232 of 285 (81.4%) of non-industry sponsored trials (NIH, non-NIH Government, and clinical research networks). Of 
the 554 studies with clinical and surrogate endpoints, 412 reported safety data - 270/332 (81.3%) drug trials, 40/53 (75.4%) device trials, 10/14 
(71.4) drug + device trials, and 67/154 (43.5) of other forms of intervention.
Conclusions: The nature of the funding source, for-profit versus not-for-profit, does not appear to influence the selection of primary outcome 
measures in major CV trials. The reporting of safety data in major CV trials is currently incomplete and requires further emphasis.
